Related Experiment Video
Updated: Aug 14, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Trimazosin in chronic congestive heart failure: improved left ventricular function at rest and during exercise
American Heart Journal
|November 1, 1983
Summary
The oral vasodilator trimazosin significantly improved hemodynamics in patients with chronic congestive heart failure (CHF). This medication demonstrated sustained benefits at rest and during exercise, enhancing cardiac function.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic congestive heart failure (CHF) is characterized by impaired cardiac function.
- Effective management of CHF requires interventions that improve hemodynamics.
Purpose of the Study:
- To evaluate the hemodynamic effects of the oral vasodilator trimazosin in patients with chronic CHF.
- To assess the sustained efficacy of trimazosin during maintenance therapy and exercise.
Main Methods:
- Hemodynamic parameters were assessed in 13 patients over 72 hours and in seven patients after 3 months of trimazosin therapy.
- Measurements included cardiac index, stroke work index, and pulmonary capillary wedge pressure at rest and during supine bicycle exercise.
Main Results:
- Initial administration of trimazosin increased cardiac index (+24%) and stroke work index (+37%), while decreasing pulmonary capillary wedge pressure (-26%).
- These improvements were maintained after 3 months of therapy (cardiac index +30%, stroke work index +38%, pulmonary capillary wedge pressure -38%) and during exercise.
- Withdrawal of trimazosin led to a decline in hemodynamic function.
Conclusions:
- Trimazosin demonstrates potential for sustained improvement in left ventricular function in patients with chronic CHF.
- The drug effectively enhances cardiac performance both at rest and during physical exertion.
- Trimazosin offers a therapeutic option for managing hemodynamic dysfunction in chronic heart failure.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.